ClinicalTrials.gov
ClinicalTrials.gov Menu

Interaction of Apelin and Angiotensin in the Human Forearm Circulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00901745
Recruitment Status : Completed
First Posted : May 14, 2009
Last Update Posted : August 10, 2010
Sponsor:
Information provided by:
University of Edinburgh

May 13, 2009
May 14, 2009
August 10, 2010
May 2009
April 2010   (Final data collection date for primary outcome measure)
Change in angiotensin II mediated vasoconstriction [ Time Frame: 12 months ]
Same as current
Complete list of historical versions of study NCT00901745 on ClinicalTrials.gov Archive Site
Changes in relevant neurohumoral hormones in response to apelin infusion [ Time Frame: 12 months ]
Same as current
Not Provided
Not Provided
 
Interaction of Apelin and Angiotensin in the Human Forearm Circulation
Investigating the Interaction of Apelin and Angiotensin II Peripheral Resistance Vessels in Vivo in Man

The apelin-APJ system is a relatively new discovery. It has generated interest in part due to it's apparent ability to counteract the renin-angiotensin system, which is frequently overactive in many cardiovascular disease.

Apelin has the ability to cause blood vessels to relax, increasing their diameter and hence blood flow down the blood vessel. The researchers wish to investigate the hypothesis that an infusion of apelin will reduce the effects of angiotensin II, which is know to reduce the diameter of blood vessels.

Not Provided
Interventional
Not Applicable
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
  • Heart Disease
  • Vasodilation
  • Drug: Angiotensin II
    Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
  • Drug: Noradrenaline infusion
    Infusion of up to 480 picomol/ml of noradrenaline will be infused.
  • Experimental: Infusion of apelin
    Using forearm venous occlusion plethysmography apelin will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
    Interventions:
    • Drug: Angiotensin II
    • Drug: Noradrenaline infusion
  • Active Comparator: Sodium nitroprusside infusion
    Using forearm venous occlusion plethysmography sodium nitroprusside will be infused to cause reduction in forearm blood flow. Infusion of angiotensin II and noradrenaline will given and vasoconstriction will be assessed. Blood samples for the infused arm and contra-lateral arm will be taken at regular time points to assess local and systemic changes in relevant hormones.
    Interventions:
    • Drug: Angiotensin II
    • Drug: Noradrenaline infusion
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
Same as current
April 2010
April 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • > 18 years old
  • Healthy volunteers

Exclusion Criteria:

  • Lack of informed consent
  • Age < 18 years,
  • Current involvement in other research studies,
  • Systolic blood pressure >190 mmHg or <100 mmHg
  • Malignant arrhythmias
  • Renal or hepatic failure
  • Haemodynamically significant aortic stenosis
  • Severe or significant co morbidity
  • Women of childbearing potential.
  • Any regular medication

    • Previous history of any cardiovascular disease
Sexes Eligible for Study: All
18 Years to 85 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00901745
FS/09/019/26905 - 1b
No
Not Provided
Not Provided
Dr Gareth Barnes, University of Edinburgh
University of Edinburgh
Not Provided
Principal Investigator: Gareth D Barnes, MBChB University of Edinburgh
University of Edinburgh
May 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP